MedLife takes over pathological anatomy and molecular biology lab Onco Team Diagnostic

Private medical services provider MedLife announced the acquisition of a majority stake in medical company Onco Team Diagnostic, the first lab focused on pathological anatomy and molecular biology to be added to its portfolio. The unit joins the existing laboratories in the group (MedLife Grivita, MedLife Brasov, Laboratory Panduri, etc.) providing tests on this segment.

The Onco Team Diagnostic Laboratory is located in Bucharest and has over 6 years of activity on the market. It is one of the reference labs for this segment, providing patients with a fully automated system of pathology, immunohistochemistry and molecular biology. The medical team, made up of doctors with more than 20 years’ experience, ensures a diagnosis of maximum accuracy, using leading methodologies and techniques in the field.

“Through this acquisition we strengthen the activity on the laboratory side, offering patients excellence in the processing of tests. The lab is equipped with state-of-the-art technology, in line with MedLife standards, and the team consists of super-specialized physicians on their niche. It is the first step in our expansion and development project, which was approved by the shareholders a few months ago. This is a sustained period of acquisitions, at the end of which we want to consolidate our leading position,” said Mihai Marcu, the President and CEO of MedLife Group.

At the same time, Onco Team Diagnostic is one of the providers of laboratory services that have an ongoing contract with the Health Insurance House of the Municipality of Bucharest (CASMB), as well as with the Health Insurance Houses of two other counties – Arges and Dambovita . This way, the lab covers a wide range of tests from the histopathology and immunohistochemistry segments, as well as cytodiagnostic examinations.

“We are pleased to become part of the largest private health system. This partnership is primarily a medical partnership, our patients will benefit from multidisciplinarity. At the same time, it is also a great opportunity to develop our business, taking advantage of all the strategy and support of the group in the medical and management areas. We will take an important step in the company’s evolution, and in this way we will advance in the complexity and efficiency of the medical service, ensuring clinico-pathological diagnoses of a high accuracy,” said Adina Balan, one of the lab’s shareholders.

Read more about

MedLife strengthens leadership in genetic sequencing with Personal Genetics acquisition

read more

According to company representatives, in 2018 the unit registered a turnover of EUR 1.1 million.

By taking over the Onco Team Diagnostic laboratory, MedLife group reaches a portfolio of 24 acquired companies.